Obicetrapib is primarily investigated for its potential in cardiovascular disease management. It functions as a cholesterol ester transfer protein (CETP) inhibitor, aiming to increase high-density lipoprotein (HDL) cholesterol levels while reducing low-density lipoprotein (LDL) cholesterol. This dual action makes it a promising candidate for reducing the risk of atherosclerosis and other heart-related conditions. Clinical trials are ongoing to evaluate its efficacy and safety in patients with dyslipidemia, particularly those who do not achieve optimal cholesterol levels with existing therapies. If proven effective, it could become a valuable addition to lipid-lowering treatment regimens, potentially improving outcomes for individuals at high risk of cardiovascular events.